Logo image of VVY.AS

VIVORYON THERAPEUTICS NV (VVY.AS) Stock Fundamental Analysis

AMS:VVY - Euronext Amsterdam - NL00150002Q7 - Common Stock - Currency: EUR

1.93  +0.03 (+1.58%)

Fundamental Rating

2

VVY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. While VVY has a great health rating, there are worries on its profitability. VVY does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VVY has reported negative net income.
VVY had a negative operating cash flow in the past year.
VVY had negative earnings in each of the past 5 years.
VVY had a negative operating cash flow in each of the past 5 years.
VVY.AS Yearly Net Income VS EBIT VS OCF VS FCFVVY.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

With a Return On Assets value of -166.81%, VVY is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
VVY has a Return On Equity of -202.73%. This is in the lower half of the industry: VVY underperforms 68.06% of its industry peers.
Industry RankSector Rank
ROA -166.81%
ROE -202.73%
ROIC N/A
ROA(3y)-77.76%
ROA(5y)-61.17%
ROE(3y)-96.83%
ROE(5y)-74.36%
ROIC(3y)N/A
ROIC(5y)N/A
VVY.AS Yearly ROA, ROE, ROICVVY.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VVY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VVY.AS Yearly Profit, Operating, Gross MarginsVVY.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 400 600

More info and screens

7

2. Health

2.1 Basic Checks

VVY does not have a ROIC to compare to the WACC, probably because it is not profitable.
VVY has more shares outstanding than it did 1 year ago.
VVY has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, VVY has an improved debt to assets ratio.
VVY.AS Yearly Shares OutstandingVVY.AS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
VVY.AS Yearly Total Debt VS Total AssetsVVY.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

VVY has an Altman-Z score of -8.15. This is a bad value and indicates that VVY is not financially healthy and even has some risk of bankruptcy.
VVY's Altman-Z score of -8.15 is on the low side compared to the rest of the industry. VVY is outperformed by 70.83% of its industry peers.
There is no outstanding debt for VVY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.15
ROIC/WACCN/A
WACC7.12%
VVY.AS Yearly LT Debt VS Equity VS FCFVVY.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

VVY has a Current Ratio of 9.37. This indicates that VVY is financially healthy and has no problem in meeting its short term obligations.
VVY's Current ratio of 9.37 is amongst the best of the industry. VVY outperforms 95.83% of its industry peers.
VVY has a Quick Ratio of 9.37. This indicates that VVY is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 9.37, VVY belongs to the best of the industry, outperforming 95.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.37
Quick Ratio 9.37
VVY.AS Yearly Current Assets VS Current LiabilitesVVY.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

0

3. Growth

3.1 Past

VVY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.14%.
EPS 1Y (TTM)-7.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, VVY will show a small growth in Earnings Per Share. The EPS will grow by 0.92% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.13%
EPS Next 2Y16.99%
EPS Next 3Y9.38%
EPS Next 5Y0.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VVY.AS Yearly Revenue VS EstimatesVVY.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 500M 1B 1.5B
VVY.AS Yearly EPS VS EstimatesVVY.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 10 20 30 40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VVY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VVY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VVY.AS Price Earnings VS Forward Price EarningsVVY.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VVY.AS Per share dataVVY.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.99%
EPS Next 3Y9.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VVY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIVORYON THERAPEUTICS NV

AMS:VVY (3/7/2025, 7:00:00 PM)

1.93

+0.03 (+1.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-12 2024-09-12/bmo
Earnings (Next)04-22 2025-04-22/amc
Inst Owners14.38%
Inst Owner ChangeN/A
Ins Owners10.2%
Ins Owner ChangeN/A
Market Cap50.32M
Analysts77.5
Price Target5.36 (177.72%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-66.86%
PT rev (3m)-71.89%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)5.42%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.6
P/tB 3.85
EV/EBITDA N/A
EPS(TTM)-1.2
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS-0.14
BVpS0.54
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -166.81%
ROE -202.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-77.76%
ROA(5y)-61.17%
ROE(3y)-96.83%
ROE(5y)-74.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover-0.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.37
Quick Ratio 9.37
Altman-Z -8.15
F-Score2
WACC7.12%
ROIC/WACCN/A
Cap/Depr(3y)110.94%
Cap/Depr(5y)86.01%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
EPS Next Y16.13%
EPS Next 2Y16.99%
EPS Next 3Y9.38%
EPS Next 5Y0.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.92%
EBIT Next 3Y-24.02%
EBIT Next 5Y6.22%
FCF growth 1Y-0.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.65%
OCF growth 3YN/A
OCF growth 5YN/A